Shares of PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) dropped 1.2% during trading on Friday . The stock traded as low as $0.7321 and last traded at $0.7588. Approximately 75,748 shares traded hands during mid-day trading, an increase of 758% from the average daily volume of 8,831 shares. The stock had previously closed at $0.7680.
PharmaCyte Biotech Trading Up 1.4%
The stock’s 50-day moving average is $0.75 and its two-hundred day moving average is $0.77.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical?stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose?based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
Read More
- Five stocks we like better than PharmaCyte Biotech
- Capri’s Turnaround Is Taking Shape, But Is the Stock a Buy Yet?
- SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
